Timolol Maleate API (active pharmaceutical ingredient) is a non-selective beta-adrenergic receptor blocker widely used in pharmaceutical formulations, particularly ophthalmic dosage forms.

The API is primarily indicated for the treatment of glaucoma and ocular hypertension due to its ability to lower intraocular pressure.

Timolol Maleate API works by reducing the production of aqueous humor in the ciliary body of the eye.

By blocking beta-adrenergic receptors, Timolol Maleate decreases fluid secretion, thereby lowering intraocular pressure and helping to prevent optic nerve damage associated with glaucoma.

Timolol Maleate API is a white to off-white crystalline powder which is freely soluble in water and alcohol.

It exhibits good chemical stability under controlled pH conditions, which is critical for ophthalmic dosage forms.

Timolol Maleate is commonly formulated as ophthalmic dosage forms such as ophthalmic solutions, ophthalmic gels, and sustained-release eye drops. Timolol Maleate active pharmaceutical ingredient (API) may also be incorporated into combination therapies with other antiglaucoma agents for enhanced therapeutic efficacy.

Timolol Maleate is suitable for controlled-release ophthalmic systems, including gels and polymer-based drug delivery systems, which help prolong ocular residence time, reduce dosing frequency, and improve patient compliance.

Timolol Maleate from Gangwal Healthcare is manufactured in compliance with major global pharmacopoeial standards, including IP, BP, EP, and USP-NF.

This multi-pharmacopoeial conformity ensures consistent quality, purity, and performance, making the Timolol Maleate API suitable for regulated markets and a wide range of pharmaceutical formulations.